{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-033086","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.138732+00:00","generated_at":"2026-06-18T00:26:02.378290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront","bullets":["Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).","Cash and equivalents $20.3M as of Dec 31, 2022.","Entered strategic collaboration with AbbVie for up to 10 novel antibody-target pairs; $30M upfront plus up to $70M platform milestones.","Per target: up to $120M in development/commercial milestones, $150M in sales milestones, plus tiered royalties.","Seeking partner for COVID-19 antibody cocktail IMM-BCP-01 after Phase 1b cohort completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-033086","json":"https://secwatch.observer/filing/0001104659-23-033086.json","markdown":"https://secwatch.observer/filing/0001104659-23-033086.md","text":"https://secwatch.observer/filing/0001104659-23-033086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/0001104659-23-033086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923033086/tm239583d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:26:02.378290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}